BillionToOne, Inc.

BillionToOne, Inc. reported strong financial results for the second quarter and first half of 2026. For Q2 2026, revenue increased to $109.4 million from $66.6 million in Q2 2025, and the company achieved a net income of $8.05 million, a significant improvement from a net loss of $0.25 million in the prior year. The company also saw substantial growth in its prenatal and oncology segments, and entered into new agreements with payors that contributed to revenue.

BillionToOne reported strong financial results for the second quarter ended June 30, 2026, with total revenue increasing 64% year-over-year to $109.4 million and achieving a net income of $8.1 million. The company also saw significant growth in both prenatal and oncology clinical testing revenue, alongside an improved gross profit margin of 70% and positive free cash flow of $5.1 million. BillionToOne reiterated its full-year 2026 revenue guidance of $450 million to $465 million and announced upcoming expansions and launches for its Unity Fetal Risk Screen and Northstar Origin products.

BillionToOne, Inc. announced its plan to release financial results for the second quarter ended June 30, 2026, after market close on Wednesday, August 5, 2026. The company will host a conference call on the same day at 1:30 PM Pacific Time / 4:30 PM Eastern Time to discuss these results. A live and archived webcast will be accessible on the investor relations section of BillionToOne's website.

BillionToOne, Inc. has entered into a 12-year lease agreement for approximately 62,659 square feet of office and laboratory space in Union City, CA. This expansion is intended to provide additional laboratory capacity, specifically for oncology products, and will triple the company's current oncology-dedicated lab space. The new facility will expand BillionToOne's total facility space by about 16% and is anticipated to commence around August 1, 2027. The aggregate base rent over the term is approximately $46.7 million, with the landlord providing a 12-month rent abatement and a tenant improvement allowance of up to $12.5 million.

BillionToOne, Inc. held its Annual Meeting of Stockholders on June 10, 2026. At the meeting, stockholders approved the election of Oguzhan Atay and Akshay Rai as Class I directors, who will serve until the 2029 annual meeting. Additionally, the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.

BillionToOne, Inc., a next-generation molecular diagnostics company, announced that its management will participate in the William Blair 46th Annual Growth Stock Conference. The presentation is scheduled for Tuesday, June 2, 2026, from 12:40pm to 1:10pm Central Time. A live and archived webcast of the presentation will be accessible on the company's investor relations website.

BillionToOne, Inc. reported strong financial results for the first quarter of 2026, with revenue increasing by 83.8% year-over-year to $108.39 million. The company swung to a net income of $17.97 million, a significant improvement from a net loss of $3.99 million in the prior-year period. This performance was driven by substantial growth in both prenatal and oncology testing services, alongside an amendment to its partnership agreement with Johnson & Johnson.

BillionToOne, Inc. reported strong financial results for the first quarter ended March 31, 2026, with total revenue increasing 84% year-over-year to $108.4 million and achieving a net income of $18.0 million. The company also raised its full-year 2026 revenue guidance to a range of $450 million to $465 million, reflecting 48% to 52% growth over 2025. Additionally, BillionToOne launched Unity ConfirmTM, a new non-invasive prenatal confirmation assay.

BillionToOne, Inc. announced its plan to release financial results for the first quarter ended March 31, 2026. The results will be disclosed after the market closes on Wednesday, May 6, 2026. The company will also host a conference call and webcast on the same day at 4:30 PM Eastern Time to discuss the financial performance.